The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of the liposomal RNAi therapeutic Atu027 in patients with advanced cancer.
Beate Schultheis
No relevant relationships to disclose
Dirk Strumberg
No relevant relationships to disclose
Ansgar Santel
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Frank Gebhardt
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Michael Khan
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Oliver Keil
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Klaus Giese
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Jörg Kaufmann
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics